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Abstract
The aim of the present study was to compare the toxic effects of
fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg)
administered during the third week of pregnancy on early develop-
ment of rats. Both antidepressants were administered by gavage on
pregnancy days 15 to 20 to groups of 10 to 12 animals each. Duration
of gestation, food and water consumption, number of live pups and
birth weight were recorded. Litters were culled to six pups at birth (day
1) and followed for growth until weaning (day 25). On day 60, a male
and a female from each litter were injected with the 5-HT1 agonist,
5-methoxy-N,N-dimethyltryptamine (6 mg/kg, ip) and the serotoner-
gic syndrome was graded. Fluoxetine but not venlafaxine reduced the
duration of pregnancy when compared to the control (C) group (F =
21.1 days and C = 21.6 days, mean, P<0.02; maximum = 22 days and
minimum = 21 days in both groups). The highest doses of both
fluoxetine, 16 mg/kg (F16), and venlafaxine, 80 mg/kg (V80), reduced
the food intake of pregnant rats, resulting in different rates of body
weight gain during treatment (from pregnancy day 15 to day 20): F16
= 29.0 g, V80 = 28.7 g vs C = 39.5 g (median). Birth weight was
influenced by treatment and sex (P<0.05; two-way ANOVA). Both
doses of fluoxetine or venlafaxine reduced the body weight of litters;
however, the body weight of litters from treated dams was equal to the
weight of control litters by the time of weaning. At weaning there was
no significant difference in weight between sexes. There was no
difference among groups in number of live pups at birth, stillbirths,
mortality during the lactation period or in the manifestation of seroto-
nergic syndrome in adult rats. The occurrence of low birth weight
among pups born to dams which did not show reduced food ingestion
or reduction of body weight gain during treatment with lower doses of
fluoxetine or venlafaxine suggests that these drugs may have a delete-
rious effect on prenatal development when administered during preg-
nancy. In addition, fluoxetine slightly but significantly affected the
duration of pregnancy (about half a day), an effect not observed in the
venlafaxine-treated groups.
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The puerperal period has long been rec-
ognized as an increased risk factor for be-
havioral disorders and mental illness. Epide-
miological studies have shown a dramatic
increase in the rates of first new psychiatric
episodes for women during the 3-month pe-
riod following childbirth. At least 80% of
these psychiatric episodes represent mood
disorders (1). On the other hand, vulnerabil-
ity of pregnancy to mood disorders was rec-
ognized only recently (2,3). Non-psychotic
depressive illness affects 38% of women in
the third trimester of pregnancy (2). More-
over, some anxiety disorders such as panic
disorders may worsen during pregnancy, re-
quiring pharmacological treatment (4). Ma-
ternal depression, if not treated, can lead to
chronic or recurrent mood disorder in the
mother (5) and disturbances in behavior and
cognitive development in the infant (6). Phar-
macological therapy of depression or anxi-
ety during pregnancy creates the clinical
dilemma of exposing the unborn brain to
psychoactive drugs. On the other hand, be-
cause a large proportion of pregnancies are
unplanned, fetal exposure may occur when a
woman of childbearing age is using an anti-
depressive medication. Fluoxetine was the
first of several highly selective inhibitors of
neuronal serotonin uptake that were shown
to be effective in the treatment of clinical
depression (7). Since then, fluoxetine and
the new group of drugs known as specific
reuptake inhibitors have been widely used
for a variety of medical conditions. Other
nonselective serotonin reuptake inhibitors
such as venlafaxine are also used to treat
depressive disorders. Notwithstanding the
widespread use and increasing potential ap-
plication of serotonin reuptake inhibitors
during pregnancy or during breast feeding,
little is known about their potential develop-
mental toxicology. A few studies on the
effects of fluoxetine on development were
published. The study by Nulman et al. (8)
indicates that it is not teratogenic and does
not affect the neurodevelopment of children
exposed during the first trimester of gesta-
tion. In contrast to these results, in vitro
developmental toxicity studies have demon-
strated that fluoxetine and sertraline, an-
other serotonin reuptake inhibitor, disrupt
normal craniofacial morphogenesis in mouse
embryos, presumably by inhibiting seroto-
nin uptake into differentiating craniofacial
epithelia (9). Other findings from in vivo
developmental assessments are contradic-
tory. Some reports do not show functional or
behavioral deficits in the offspring (10) but
others have reported behavioral alterations
in the adult progeny as a result of prenatal
exposure (11). To our knowledge, prospec-
tive controlled studies on the developmental
toxicology of venlafaxine have not been per-
formed. The latter drug purportedly may be
effective in some cases of refractory depres-
sion (12), and thus its possible prescription
during pregnancy or during the puerperal
period should be considered.
The aim of the present study was to com-
pare the toxic effects of fluoxetine and ven-
lafaxine on the development of rat offspring
exposed during pregnancy. Comparisons of
the toxicologic profiles of these drugs in the
same study may provide useful information
for clinical situations where an option for
pharmacological therapy is required. In or-
der to start this toxicologic comparison of
the two drugs during the developmental pro-
cess, we selected the third week of preg-
nancy as the time of drug exposure. It is
known from the available literature (13) that
the peak of cell differentiation for serotonin-
ergic neurons occurs on gestational days 15-
16 and by gestational day 19 the distribution
of serotonin neurons resembles that found in
the adult. Therefore, these drugs, both in-
hibitors of serotonin reuptake, might inter-
fere with the developing serotoninergic sys-
tem at this critical time. Experimental stud-
ies on the effects of antidepressants during
the last part of pregnancy are also important
if we consider that maternal depression may
occur in 38% of women during the third
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trimester of pregnancy (2). Thus, questions
about the interference of antidepressants with
labor and their potential for inducing prema-
ture births and presenting fetotoxicity must
be raised.
Female Wistar rats from our breeding
colony weighing approximately 200 g were
mated overnight to males of the same stock,
in a harem system. Vaginal smears were
collected and the presence of sperm was
used to determine gestational day 0. Ten to
12 pregnant dams per group were exposed to
either 8 or 16 mg/kg of fluoxetine (F8 or F16)
or 40 or 80 mg/kg of venlafaxine (V40 or
V80) administered intragastrically by ga-
vage from gestational day 15 to 20. A control
group (C) was gavaged with the vehicle (wa-
ter). Food and water consumption during
treatment was recorded. Doses of fluoxetine
were selected from a previous experimental
study on the embryotoxicity of fluoxetine
carried out on rats (14). In this study, the
developmental no observed adverse effect
level (NOAEL) was 12.5 mg/kg. We chose 8
and 16 mg/kg dose levels which were lower
and slightly higher than the NOAEL for
embryotoxicity in order to look for the po-
tential functional toxicity of lower doses and
in order to obtain information for the design
of future studies on behavioral teratology.
Functional and behavioral toxicity is assumed
to occur at dose levels lower than those
involved in embryotoxicity. Less informa-
tion was available on the developmental ef-
fects of venlafaxine. Therefore, we based
our dose selection on the information from
the manufacturer referring to experimental
studies in which the only toxic effect re-
ported was delayed rat development at the
dose of 80 mg/kg. In our study we selected
40 and 80 mg/kg. Thus, we used a weight
ratio of 5:1 for venlafaxine and fluoxetine in
the present study. It should be pointed out
that this same proportion of doses is reported
in clinical practice (maximum dose levels of
80 mg/day and 275 mg/day for fluoxetine
and venlafaxine, respectively).
From day 21 of pregnancy onwards, cages
were inspected twice daily to detect births.
Gestation length, number of live pups at
birth and birth weight were recorded. Litters
were culled to six pups at birth (day 1).
Maternal behavior was evaluated daily at
9:00 a.m. by recording whether the mother
was in the nest. Weaning was performed on
day 25 and pups were weighed and separated
by gender. On day 60, one male and one
female from each litter were injected with
the 5HT1 agonist, 5-methoxy-N,N-dimethyl-
tryptamine (6 mg/kg, ip) and behavioral re-
sponses (forepaw treading and hind limb
abduction) were recorded in 5 independent
evaluations along 16 min and graded accord-
ing to intensity (15). The ranked intensity
scale was 0 = absent, 1 = present, 2 = moder-
ate and 3 = intense. Observers were blind to
animal treatment.
Fluoxetine but not venlafaxine signifi-
cantly shortened pregnancy (Table 1). The
effect was mild (around half a day) but con-
sistent at the two dose levels. The effect was
statistically significant when groups F8 and
F16 were combined and compared to the
control group. Venlafaxine had no effect
even when data for the two dose levels were
combined. Both fluoxetine 16 mg/kg and
venlafaxine 80 mg/kg decreased food con-
sumption and weight gain of the dams during
treatment, whereas the lower doses of each
compound did not affect food intake or weight
gain of dams (Table 1). Birth weight was
affected by treatment and by sex (Figure 1).
A decrease in body weight at birth was de-
tected in all the litters of dams treated with
the low (F8, V40) or high doses (F16, F80)
of fluoxetine or venlafaxine as compared to
the control group. At birth females had lower
body weight than males. The effect on preg-
nancy duration may be linked to the intense
and selective serotonergic action of fluoxe-
tine since venlafaxine, a nonselective
reuptake inhibitor (12), did not affect preg-
nancy duration. The effect of treatment of
dams with fluoxetine or venlafaxine on prog-
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Figure 1 - Effects on offspring of fluoxetine or venlafaxine administered to pregnant rats. Fluoxetine (8 (F8) or 16
(F16) mg/kg) or venlafaxine (40 (V40) or 80 (V80) mg/kg) was administered by gavage daily from gestational day 15
to 20. The control (C) group was treated with water. Litters were used as the unit for statistical analysis. Groups
were compared by two-way (body weight) or one-way (live pups at birth) ANOVA followed by the Student t-test or
the Kruskal-Wallis test and by the Mann-Whitney U-test (mortality during lactation). Values are reported as the mean
± SD. *P<0.05 compared to controls and to female rats of the same group (P<0.05 for treatment and sex: two-way
ANOVA).
N
um
be
r 
of
 li
ve
 p
up
s 
at
 b
irt
h 15
10
5
0
1.5
1.0
0.5
0.0N
um
be
r 
of
 d
ea
d 
pu
ps
 d
ur
in
g
la
ct
at
io
n
B
od
y 
w
ei
gh
t 
at
 b
irt
h 
(g
)
7.5
5.0
2.5
0.0
B
od
y 
w
ei
gh
t 
at
 w
ea
ni
ng
 (g
)
75
50
25
0
Male Female FemaleMale
C F8 F16 V40 V80
Table 1 - Effect of fluoxetine or venlafaxine administered to pregnant rats from day 15 to day 20 of gestation.
Fluoxetine (8 (F8) or 16 (F16) mg/kg) or venlafaxine (40 (V40) or 80 (V80) mg/kg) was administered by gavage
daily from gestational day 15 to 20. The control (C) group was treated with water. Data on food consumption
represents total consumption from day 15 to 20. Weight gain is the difference in body weight between day 20
and 15. Groups were compared by the Kruskal-Wallis test followed by the Mann-Whitney U-test. Values are
reported as the mean and maximum and minimum values (between parentheses). Statistical analysis: a: ¹ F8;
b: ¹ V40; c: ¹ C; d: F<C; P = 0.02.
C (N = 10) F8 (N = 11) F16 (N = 12) V40 (N = 11) V80 (N = 11)
Food consumption (g) 133.5 126.0 108.7a,c 130.6 114.7b,c
(day 15 to 20) (117.3-145.3) (109.3-141.3) (90.9-131.3) (108.1-169.9) (79.1-133.8)
Weight gain (g) 39.5 38.6 29.0a,c 42.2 28.7b
(day 15 to 20) (23.6-49.6) (25.6-52.9) (14.8-43.7) (15.0-51.1) (-15.9-48.3)
Duration of gestation 21.6 21.1d 21.2d 21.4 21.6
(days) (21-22) (21-22) (21-22) (21-22) (21-24)
eny body weight at birth was apparent for all
treated groups, even those which received
the lower doses of the compounds. Ven-
lafaxine or fluoxetine 8 or 40 mg/kg, respec-
tively, did not decrease food consumption or
body weight in dams although their litters
were born with lower body weight than con-
trols (Table 1 and Figure 1), indicating that
* * * *
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the effect on offspring body weight is not an
indirect effect caused by reduced maternal
food intake. Thus, the possibility that these
compounds had a direct fetotoxic effect on
unborn pups must be considered. By wean-
ing time, at 25 days of age, body weight was
the same in all treated and control groups.
Recovery of body weight was confirmed in
adulthood (110 days), when pharmacologi-
cal testing was performed (male: C = 322.6 –
4.6 g, F8 = 322.1 – 5.7 g, F16 = 328.7 – 25.7
g, V40 = 326.2 – 6.9 g, V80 = 327 – 19.5 g
and female: C = 209.3 – 0.8 g, F8 = 216.5 –
4.2 g, F16 = 208.2 – 3.9 g, V40 = 199.4 – 2.1
g, V80 = 208.8 – 5.7 g). The recovery of
body weight to control levels during lacta-
tion is common to other models such as in
utero malnutrition which show low body
weight at birth (16). Females of all groups
had lower body weight than males of the
same group. By the time of weaning, body
weight of females was the same as that of
males in all groups.
The number of live pups at birth and
mortality during lactation were the same in
control and treated groups. Maternal behav-
ior, as measured, apparently was not af-
fected by treatment with either fluoxetine or
venlafaxine. Adult animals tested for behav-
ioral responses to 5-methoxy-N,N-dimeth-
yltryptamine showed the same grade of re-
sponses whether from litters born to control
or treated dams. Behavioral scores derived
from the sum of 5 grades given in independ-
ent evaluations along 16 min were (median):
C = 9; F8 = 8.5; F16 = 9; V40 = 9.5 and V80
= 9 (Kruskal-Wallis, P>0.05). Although these
behavioral data suggest that the serotoniner-
gic system was not affected under the exper-
imental conditions studied, additional stud-
ies on serotonin brain levels or turnover are
needed before any definitive conclusion can
be reached.
The demonstration of a reduction in ges-
tation length caused by fluoxetine and the
reduction of birth weight caused by both
fluoxetine and venlafaxine are indications of
the potential toxic effects of these compounds
on the progeny when administered during
pregnancy. Extrapolation to a clinical situa-
tion would call for careful considerations
regarding dose relationships and interspe-
cies differences. However, any indication of
prenatal toxicity in animals for medications
of potential use during pregnancy should be
examined carefully.
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